{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:25:16Z","timestamp":1783617916368,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA155524"],"award-info":[{"award-number":["R21CA155524"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6610-20"],"award-info":[{"award-number":["6610-20"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41375-022-01622-0","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T14:08:02Z","timestamp":1654870082000},"page":"2022-2031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials"],"prefix":"10.1038","volume":"36","author":[{"given":"Mohammed O.","family":"Gbadamosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek M.","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman H.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3702-7923","authenticated-orcid":false,"given":"Rhonda","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseyi","family":"Olabige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3036-4748","authenticated-orcid":false,"given":"Nam H. K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"De Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy A.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Gamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-0007","authenticated-orcid":false,"given":"Jatinder K.","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"1622_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u20131152.","journal-title":"N Engl J Med"},{"key":"1622_CR2","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","volume":"93","author":"EL Sievers","year":"1999","unstructured":"Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678\u201384.","journal-title":"Blood"},{"key":"1622_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/bc010021y","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody\u2014calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13:47\u201358.","journal-title":"Bioconjug Chem"},{"key":"1622_CR4","doi-asserted-by":"publisher","unstructured":"Jen EY, Ko C-W, Lee JE, Del Valle PL, Aydanian A, Jewell C, et al. FDA Approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3179.","DOI":"10.1158\/1078-0432.CCR-17-3179"},{"key":"1622_CR5","doi-asserted-by":"publisher","unstructured":"Norsworthy KJ, Ko C, Lee JE, Liu J, John CS, Przepiorka D, et al. FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33\u2010positive acute myeloid leukemia. Oncologist. 2018. https:\/\/doi.org\/10.1634\/theoncologist.2017-0604.","DOI":"10.1634\/theoncologist.2017-0604"},{"key":"1622_CR6","doi-asserted-by":"publisher","unstructured":"Gbadamosi M, Meshinchi S, Lamba JK Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. Future Oncol. 2018; 14. https:\/\/doi.org\/10.2217\/fon-2018-0325.","DOI":"10.2217\/fon-2018-0325"},{"key":"1622_CR7","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","volume":"119","author":"JA Pollard","year":"2012","unstructured":"Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119:3705\u20133711.","journal-title":"Blood"},{"key":"1622_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","volume":"34","author":"JA Pollard","year":"2016","unstructured":"Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III children\u2019s oncology group trial AAML0531. J Clin Oncol. 2016;34:747\u2013755.","journal-title":"J Clin Oncol"},{"key":"1622_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.2016.71.2513","volume":"35","author":"JK Lamba","year":"2017","unstructured":"Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: Report from randomized phase III children\u2019s oncology group trial AAML0531. J Clin Oncol. 2017;35:674\u20132682.","journal-title":"J Clin Oncol"},{"key":"1622_CR10","doi-asserted-by":"crossref","unstructured":"Chauhan L, Shin M, Wang Y-C, Loken M, Pollard J, Aplenc R, et al. CD33_PGx6_Score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: a report from the Children\u2019s Oncology Group. JCO Precis Oncol. 2019:3;1\u201315.","DOI":"10.1200\/PO.18.00387"},{"key":"1622_CR11","doi-asserted-by":"publisher","unstructured":"Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, et al. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children\u2019s Oncology Group AAML0531 trial. Blood Cancer J. 2019; 9. https:\/\/doi.org\/10.1038\/s41408-019-0211-y.","DOI":"10.1038\/s41408-019-0211-y"},{"key":"1622_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1126\/science.3240341","volume":"240","author":"N Zein","year":"1988","unstructured":"Zein N, Sinha A, McGahren W, Ellestad G. Calicheamicin yI: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240:198\u2013201.","journal-title":"Science"},{"key":"1622_CR13","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1021\/bi00065a013","volume":"32","author":"PC Dedon","year":"1993","unstructured":"Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry. 1993;32:3617\u20133622.","journal-title":"Biochemistry"},{"key":"1622_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1568-7864(02)00235-5","volume":"2","author":"K Elmroth","year":"2003","unstructured":"Elmroth K, Nygren J, M\u00e5rtensson S, Ismail IH, Hammarsten O. Cleavage of cellular DNA by calicheamicin gamma1. DNA Repair. 2003;2:363\u2013374.","journal-title":"DNA Repair"},{"key":"1622_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1021\/tx00027a001","volume":"5","author":"PC Dedon","year":"1992","unstructured":"Dedon PC, Goldberg IH. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chem Res Toxicol. 1992;5:311\u2013332.","journal-title":"Chem Res Toxicol"},{"key":"1622_CR16","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.1074\/jbc.TM117.000374","volume":"293","author":"NR Pannunzio","year":"2018","unstructured":"Pannunzio NR, Watanabe G, Lieber MR. Nonhomologous DNA end-joining for repair of DNA double-strand breaks. J Biol Chem. 2018;293:10512\u201310523.","journal-title":"J Biol Chem"},{"key":"1622_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","volume":"79","author":"MR Lieber","year":"2010","unstructured":"Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181\u2013211.","journal-title":"Annu Rev Biochem"},{"key":"1622_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.clon.2014.02.004","volume":"26","author":"A Shibata","year":"2014","unstructured":"Shibata A, Jeggo PA. DNA double-strand break repair in a cellular context. Clin Oncol. 2014;26:243\u2013249.","journal-title":"Clin Oncol"},{"key":"1622_CR19","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1182\/blood-2002-07-2311","volume":"101","author":"D Amico","year":"2003","unstructured":"Amico D, Barbui AM, Erba E, Rambaldi A, Introna M. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;101:4589\u20134597.","journal-title":"Blood"},{"key":"1622_CR20","doi-asserted-by":"publisher","first-page":"e53518","DOI":"10.1371\/journal.pone.0053518","volume":"8","author":"DB Rosen","year":"2013","unstructured":"Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, et al. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 2013;8:e53518.","journal-title":"PLoS One"},{"key":"1622_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fonc.2020.00127","volume":"10","author":"MI Carr","year":"2020","unstructured":"Carr MI, Zimmermann A, Chiu L-Y, Zenke FT, Blaukat A, Vassilev LT. DNA-PK inhibitor, M3814, as a new combination partner of mylotarg in the treatment of acute myeloid leukemia. Front Oncol. 2020;10:127.","journal-title":"Front Oncol"},{"key":"1622_CR22","doi-asserted-by":"crossref","unstructured":"Godwin CD, Bates OM, Jean SR, Laszlo GS, Garling EE, Beddoe ME, et al. Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia. Leuk Lymphoma. 2020;61:2990\u20132994.","DOI":"10.1080\/10428194.2020.1786553"},{"key":"1622_CR23","doi-asserted-by":"publisher","unstructured":"Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, Meshinchi S, et al. CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. Leuk Lymphoma. 2019;60. https:\/\/doi.org\/10.1080\/10428194.2019.1569232.","DOI":"10.1080\/10428194.2019.1569232"},{"key":"1622_CR24","doi-asserted-by":"crossref","unstructured":"Xu Q, He S, Yu L. Clinical benefits and safety of gemtuzumab ozogamicin in treating acute myeloid leukemia in various subgroups: an updated systematic review, meta-analysis, and network meta-analysis. Front Immunol. 2021;12. https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2021.683595.","DOI":"10.3389\/fimmu.2021.683595"},{"key":"1622_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cncr.26190","volume":"118","author":"TM Cooper","year":"2012","unstructured":"Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Cancer. 2012;118:761\u2013769.","journal-title":"Cancer"},{"key":"1622_CR26","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III children\u2019s oncology group Trial AAML0531. J Clin Oncol. 2014;32:3021\u20133032.","journal-title":"J Clin Oncol"},{"key":"1622_CR27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41375-019-0604-8","volume":"34","author":"AH Elsayed","year":"2020","unstructured":"Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, et al. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2020;34:735\u2013745.","journal-title":"Leukemia"},{"key":"1622_CR28","unstructured":"Therneau TM, Atkinson EJ, Foundation M. An introduction to recursive partitioning using the RPART routines (Long). 2022:1\u201352."},{"key":"1622_CR29","doi-asserted-by":"crossref","unstructured":"Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Routledge, 2017.","DOI":"10.1201\/9781315139470"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01622-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01622-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01622-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T03:10:06Z","timestamp":1659323406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01622-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01622-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742190889.793594892","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}